Summary Several new complexes of platinum with positively charged cellular dyes have been synthesised in an effort to find chemotherapeutic drugs with increased antitumour cytotoxicity. As part of this effort, the direct cytotoxicities of some of these complexes as well as their ability to inhibit bleomycin potentially lethal damage repair (PLDR) was studied in vitro in a squamous cancer cell line of human origin . All of the new agents were more cytotoxic against exponentially growing than against plateau phase cell cultures. Exposure of cells to non-lethal drug concentrations for between 1 and 6h led to measurable inhibition of bleomycin PLDR in the case of each drug tested. In order of decreasing ability to inhibit bleomycin PLDR, Pt(fast black)2, Pt(thioflavin)2 and Pt(thionin)2 were more effective than CDDP, while Pt(methylene blue)2, Pt(Rh-123)2 and Pt(pyronin y)2 were less effective. The most directly cytotoxic agents were Pt(thioflavin)2, Pt(pyronin Y)2 and Pt(Rh-123)2 which also proved to be the least selectively toxic drugs towards exponential versus plateau phase cells. These results indicate that several of the new platinum complexes may be effective cytotoxic agents as well as effective inhibitors of DNA repair process following exposure of cells to other DNA interactive modalities.
The glycopeptide antibiotic bleomycin has demonstrated clinical usefulness in the treatment of squamous cell cancer of the head and neck (SCCHN) (Turrisi et al., 1978) , testicular tumours (Einhorn & Donahue, 1977) and lymphomas (Coltman et al., 1978) . It is used in combinations with other agents because bleomycin does not exhibit dose limiting haematopoietic toxicity (Hubbard et al., 1975) . When used as a single agent, however, complete response rates are relatively low and the emergence of drug resistance is a common problem (Crooke & Bradner, 1976) .
To various extents, mammalian tumour cells have the capacity to repair drug-and radiation-induced damage. The ability of cells to recover from potentially lethal damage has been modelled in vitro by maintaining cells in conditions which prevent them from proliferating for various times and thereby allowing time for repair processes to take place (Barranco & Townsend, 1986) .
Solid tumours and slow growing lymphomas are likely to contain large populations of non-cycling cells, which may have the capacity to repair potentially lethal damage and contribute to regrowth of the tumour. An in vitro system containing cells in stationary phase may be more analogous to the in vivo situation than are cells in exponential growth. Such an experimental model can be created by growing monolayer cell cultures to confluency under conditions of constant medium renewal without subculture. These stationary phase cultures contain a large fraction of non-cycling, but potentially clonogenic, cells (Hahn & Little, 1972 ). In such model systems, time dependent enhancement of cell survival observed with longer pre-subculture intervals following exposure to cytotoxic agents can be inferred as due to potentially lethal damage repair (PLDR) (Ray et al., 1973; Weichselbaum, 1982) .
We have employed a human squamous cell carcinoma cell line Abrams et al., 1986 ) (see Figure 1 ).
Cell line
The SCC-25 cell line was derived from the biopsy of a human squamous cell carcinoma of the tongue and was established and characterised initially by J.G. Rheinwald at the Dana-Farber Cancer Institute (Rheinwald & Beckett, 1981) . Monolayers were maintained in Dulbecco's minimum essential medium (DMEM) supplemented with 5% fetal bovine serum, hydrocortisone (0.4,ugml-1) and antibiotics (Frei et al., 1985; ). This cell line had a plating efficiency of 22+7% and a doubling time of 48h (Frei et al., 1985 (Teicher et al., 1985) . Survival studies for PLDR Stationary phase cultures of SCC-25 cells were prepared as described above. The cells were exposed to 100 Mg ml -of bleomycin for 1 h at 37°C in fresh serum-free medium. The medium covering the monolayers before treatment (depleted medium) was retained and used to cover the cultures during the delay from subculture period. After treatment with bleomycin, the dishes were rinsed twice with PBS and depleted medium was added. Platinum complexes were added to the depleted medium for the duration of the delay to the time of subculture. The concentrations of platinum complexes were 0.5iM Pt(Rh-123)2, 5MM Pt(fast black)2, 0.5 gM Pt(pyronin Y)2, 5MM Pt(thioflavin)2, 5 ,M Pt(thionin)2 and 5 pM Pt(methylene blue)2. Similar dishes which had not been treated with bleomycin were exposed to the platinum complexes for the same time periods to assess the cytotoxicity of the platinum complexes alone. Other dishes were exposed to bleomycin and each of the platinum complexes simultaneously for 1 h then immediately subcultured. Both treated and control dishes were held for 0, 1, 2, 4, 6 and 24h at 37°C; cells were then washed twice with PBS, suspended by trypsinisation and counted by haemocytometer. Comparison experimental control plates showed no significant cell loss through lysis. Known numbers of cells were plated in duplicate dishes at three dilutions for colony formation as described above .
Data analysis Quantitative analysis of survival curves was performed using the log-probit iterative least squares method of Litchfield & Wilcoxon (1949) as revised by Tallarida & Murray (1981 (Barranco & Townsend, 1986) .
Results
The structures of the platinum-dye complexes are shown in Figure 1 . The other dye complexes are analogues to Pt(Rh-123)2 with two dye molecules associated in a tight ion pair with the platinum tetrachlorodianion. The SCC-25 cell line is a well-established line derived from a human squamous carcinoma of the head and neck Pt(thioflavin)2 was the most cytotoxic of the platinum-dye complexes examined. Pt(thioflavin)2 was also more cytotoxic towards exponentially growing SCC-25 cells than toward stationary phase SCC-25 cells, but the differential was smaller (1 log at 10Mm) than with the other agents tested.
Pt(thionin)2 was similar in cytotoxicity to Pt(fast black)2. At 250Mm of Pt(thionin)2 there was about 2 logs greater kill of exponentially growing SCC-25 cells than of stationary phase SCC-25 cells. The survival curve of stationary phase SCC-25 cells exposed to Pt(methylene blue)2 was biphasic whereas that of the exponentially growing cells was linear over the dosage range examined. There was about a 30-fold greater kill of exponentially growing SCC-25 cells with Pt(methylene blue)2 than of stationary phase SCC-25 cells at 1OOMm drug concentration. Figure 3 shows the survival curve for stationary phase SCC-25 cells exposed to various concentrations of bleomycin. The survival curve is biphasic with an initial sensitive phase and a less sensitive second phase, as is common for many cell lines (Twentyman, 1984) . After stationary phase SCC-25 cells were exposed to 100pgml-1 of bleomycin for 1 h, the drug was removed and the cells were allowed various periods for PLD recovery. The capacity of the SCC-25 cell line for PLDR following X-ray treatment has been documented with a 24 h recovery ratio (R/Ro) of 6.2 (Weichselbaum, 1982) . After 24h, the SCC-25 cells showed a recovery ratio (R/Ro) of 11.0 which corresponded to an immediate survival at a drug level of 9 Mg ml -1, a dose 11-fold less than the exposure concentration of 100Mgml-1.
The recovery ratio for SCC-25 cells following bleomycin treatment increased rapidly at early time points: 4.3 at 1 h, 6.7 at 2 h and 8.7 at 4 h. The rate of recovery slowed after 4 h so that the recovery ratio was 9.8 at 6 h and 11.0 at 24 h.
Over the course of the first 6 h of PLD recovery, 0.5 uM CDDP was an effective inhibitor of PLDR (Figure 3 ). The concentration of 0.5 gM of CDDP was selected for these studies because this concentration of CDDP was essentially non-toxic over the 6h holding period. Simultaneous treatment of the cells with bleomycin and 0.5Mm CDDP for 1 h with immediate subculture resulted in cell kill equal to that of bleomycin alone. For the first hour, while R/Ro was 4.3 for bleomycin alone, with 0.5UM CDDP the R/Ro was 1.2. Between 2 and 4 h the R/Ro was 1.9-2.7 in the presence of CDDP and 6.7-8.7 without CDDP. The inhibitory effect of CDDP was still evident at the 6 h point since in the presence of CDDP the recovery ratio was 3.7 compared to 9.8 without CDDP. By 24 h post-treatment, however, the recovery ratio was 8.0, more closely approaching the 11-fold recovery observed in the absence of CDDP. This continued low level of recovery probably reflects the presence of a small concentration of bleomycin remaining inside of the cells, which at 24 h was still active.
The capability of essentially non-toxic concentrations of the six platinum-dye complexes to inhibit PLD recovery of stationary phase SCC-25 cells after exposure to bleomycin was assessed (Figure 4 ). Simultaneous exposure of stationary phase SCC-25 cells to bleomycin (100ugml-1) and each of the platinum-dye complexes for 1 h followed by immediate subculture resulted in cell kill equal to that of bleomycin alone for 1h. Pt(Rh-123)2 at a concentration of 5 gM was not a very effective inhibitor of bleomycin PLD repair. Over the 6 h recovery time period (Figure 4a) , there was less than a 1.5-fold difference between the PLDR observed in the presence or absence of Pt(Rh-123)2. Pt(fast black)2 at SliM, however, proved the most effective inhibitor of bleomycin PLDR. After exposure to Pt(fast black)2 the 1 h postbleomycin exposure recovery ratio was 1.1, by 2 h the recovery ratio increased to 2.3 and continued to increase slowly to 2.5 and to 2.7 at 4 and 6h, respectively. Thus Pt(fast black)2 (5pM) was a more effective inhibitor of Pt(pyronin Y)2 at a concentration of 0.5 gM was a moderately effective inhibitor of bleomycin PLD repair ( Figure  4b ). After 1 h of repair time, the recovery ratio was 3.1 in the presence of Pt(pyronin Y)2 compared to 4.3 in the absence of the drug. Throughout the remaining recovery period tested from 2 to 6h, the recovery ratio was 2-fold lower in the presence of 0.5 gM of Pt(pyronin Y)2 than in the absence of the drug. At this same drug concentration (0.5 Mm), Pt(thioflavin)2, was able to inhibit repair of bleomycin damage in the SCC-25 cells effectively. In the recovery period from 2 to 6 h, there was about 3.5-fold less recovery of survival in SCC-25 cells in the presence of the drug than in the absence of the drug. The recovery ratios in the presence of 0.5pM Pt(thioflavin)2 were 1.9, 2.2 and 3.0 at 2, 4 and 6 h compared with 6.7, 8.7 and 9.8 at these same time points in the absence of the repair inhibitor. The ability of Pt(methylene blue)2 at a concentration of 5pM to inhibit the repair of bleomycin damage is shown in Figure 4c . Pt(methylene blue)2 was only moderately effective as a PLD repair inhibitor with decreasing effectiveness at longer recovery times. The recovery ratio in the presence of 5pM Pt(methylene blue)2 at 1 h was 2.3 and at 6 h was 7.0 as compared with recovery ratios of 4.3 at 1 h and 9.8 at 6 h in the absence of drug. Therefore, after 1 h of recovery time there was a 1.9-fold difference between recovery in the presence and absence of the drug and after 6h of recovery time there was a 1.4-fold difference in the presence and absence of the drug. Pt(thionin)2 in a concentration of 5pM is an effective inhibitor of bleomycin PLD repair in stationary phase SCC-25 cells, giving recovery ratios of 1.0, 1.8, 2.8 and 3.7 at recovery times of 1, 2, 4 and 6 h, respectively.
Therefore, Pt(thionin)2 at a concentration of 5 pM was a more effective PLDR inhibitor than 0.5O M CDDP at short recovery times and was comparable in effectiveness to 0.5 gM CDDP at longer recovery times.
Discussion
The clinical significance of PLDR, defined here as recovery of survival before subculture, has remained controversial (Twentyman, 1984; Weichselbaum et al., 1982 Weichselbaum et al., , 1984 but it seems reasonable that drug combinations which inhibit the ability of tumour cells to repair significant portions of druginduced damage will lead to improved clinical efficacy. The ability of mammalian cells to recover from bleomycininduced damage has been well-documented both in vitro and in vivo (Barranco & Townsend, 1986) . This process can be inhibited with actinomycin D, ethanol and hyperthermia (Barranco, 1978; Twentyman, 1984) or under hypoxic conditions by misonidazole (Korbelik et al., 1985) . More recently it has been shown that some platinum complexes can inhibit the recovery of V79 cells from radiation-induced cell kill (O'Hara et al., 1986) . We have shown that, like CDDP, six other novel platinum complexes can inhibit, to various degrees, PLD recovery of stationary phase SCC-25 cells treated with bleomycin and increased repair is one possible mechanism of resistance to chemotherapeutic agents . These platinum-dye complexes were prepared in an effort to develop platinum-containing drugs which would have greater tumour selectivity than platinum-containing anticancer agents that are currently in clinical use. The interaction of several of these drugs with hyperthermia and radiation has been described in vitro . Inhibition of repair can also be an important component of drug action.
In this study, Pt(fast black)2 (5pM) was the most effective new complex as an inhibitor of PLD recovery after bleomycin exposure. Over a 6 h period, Pt(fast black)2, Pt(thioflavin)2 (0.5 gM) and Pt(thionin)2 (5 gM) were at least as effective at inhibiting recovery after treatment with bleomycin as was CDDP. Pt(Rh-123)2 (5 /uM) Pt(pyronin Y)2 (0.5 pM) and Pt(methylene blue)2 (5 pM) were less effective inhibitors of bleomycin PLD recovery in this cell line. These studies demonstrate that to differing degrees, non-toxic concentrations of these new platinum-dye complexes can prevent or postpone the recovery of survival of stationary phase SCC-25 cells exposed to bleomycin. Further experiments will be needed to define the mechanism(s) of this phenomenon whether it is interaction with a repair mechanism, interaction between bleomycin and the platinumcontaining drugs or between the platinum-containing drugs and DNA. Experiments are in progress exploring the mechanism of PLDR inhibition by these agents and the efficacy of these new platinum-containing drugs as inhibitors of radiation PLDR in vitro and as cytotoxic agents alone and in combinations with radiation, hyperthermia and other chemotherapeutic drugs in vivo.
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